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BACKGROUND: PG545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in
the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG545 also inhibits heparanase, the only
endoglycosidase which cleaves HS chains in the ECM. The aim of the study was to assess PG545 in various solid tumour and
metastasis models.
METHODS: The anti-angiogenic, anti-tumour and anti-metastatic properties of PG545 were assessed using in vivo angiogenesis, solid
tumour and metastasis models. Pharmacokinetic (PK) data were also generated in tumour-bearing mice to gain an understanding of
optimal dosing schedules and regimens.
RESULTS: PG545 was shown to inhibit angiogenesis in vivo and induce anti-tumour or anti-metastatic effects in murine models of breast,
prostate, liver, lung, colon, head and neck cancers and melanoma. Enhanced anti-tumour activity was also noted when used in
combination with sorafenib in a liver cancer model. PK data revealed that the half-life of PG545 was relatively long, with
pharmacologically relevant concentrations of radiolabeled PG545 observed in liver tumours.
CONCLUSION: PG545 is a new anti-angiogenic clinical candidate for cancer therapy. The anti-metastatic property of PG545, likely due
to the inhibition of heparanase, may prove to be a critical attribute as the compound enters phase I clinical trials.
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Tumour angiogenesis has become a prominent drug target for
cancer therapy (Carmeliet, 2005) and agents designed to target
the vascular endothelial growth factor (VEGF) family and the
fibroblast growth factor (FGF) family, along with their correspond-
ing receptor tyrosine kinases, have received considerable attention
(Sparano et al, 2004; Folkman, 2007). Anti-angiogenic therapies
directed against these targets have resulted in promising and well-
validated therapeutics, with both biologicals and small-molecule
drugs that target VEGF/VEGFR already approved for a number
of cancers. Nonetheless, most cancer deaths are due to the
development of metastases (Eccles and Welch, 2007) and
angiogenesis inhibitors do not necessarily affect this process.
Indeed, recent pre-clinical studies have raised some concerns
about the impact of such agents and metastatic disease (Ebos et al,
2009; Paez-Ribes et al, 2009; Steeg et al, 2009).
Cleavage of HS by the endo-b-glucuronidase heparanase (HPSE)
is strongly implicated in cell dissemination associated with tumour
metastasis (Barash et al, 2010). Endo-b–glucuronidase heparanase
is also involved in angiogenesis, where it releases sequestered HS-
binding angiogenic growth factors (GFs) from the extracellular
matrix (ECM) (Nakajima et al, 1988; Vlodavsky et al, 1996; Zetter,
1998; Goldshmidt et al, 2002). It also induces VEGF expression
(Zetser et al, 2006). The upregulation of HPSE in many tumours
has been linked to poor prognosis (Chen et al, 2008; Mikami et al,
2008; Rivera et al, 2008; Zheng et al, 2009). The use of heparin,
heparin derivatives, sulfated oligosaccharides and suramin and its
analogues to inhibit HPSE activity have shown promise as anti-
tumour or anti-metastatic agents (Vlodavsky et al, 1994; Marchetti
et al, 2003; Basche et al, 2006; Norrby, 2006). The clinical utility
of a mixture of sulfated oligosaccharides (PI-88) with dual
heparanase and angiogenic inhibitory activity has been previously
demonstrated in a phase II clinical trial for hepatocellular
carcinoma (HCC) (Liu et al, 2009). The limited utility of current
angiogenesis inhibitors and the critical need to address
the metastatic component of cancer together provide a strong
rationale to develop new HPSE inhibitors typified by aglycon-
functionalised sulfated oligosaccharides (Karoli et al, 2005;
Johnstone et al, 2010).
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synthetic, fully sulfated HS mimetic. We have previously demon-
strated that PG545 is a potent heparanase inhibitor (Ki¼6n M) and
a potent angiogenesis inhibitor (p1mM) using endothelial cell
assays in vitro and the ex vivo the rat aortic ring assay. Moreover,
PG545 was found to have mild anti-coagulant properties using the
activated partial thromboplastin time test and the Heptest
compared with PI-88 or earlier PG500 series compounds (Dredge
et al, 2010). In contrast to other HS mimetics which are mixtures,
PG545 is a single molecular entity. PG545 induces potent anti-
angiogenic activity in vivo together with broad acting pre-clinical
anti-tumour and anti-metastatic efficacy with a pharmacokinetic
(PK) profile to support less frequent dosing compared with other
HS mimetics. An open-label, single centre phase I study of the
safety and tolerability of PG545 in patients with advanced solid
tumours commenced in late 2010 (http://www.clinicaltrials.gov).
MATERIALS AND METHODS
Compound synthesis and preparation
PG545 is a fully sulfated tetrasaccharide functionalised with a
cholestanyl aglycon (Figure 1) designed at Progen Pharmaceuticals
Ltd (Brisbane, QLD, Australia). PG545 and radiolabeled PG545,
the latter being synthesised from [1a,2a(n)-
3H]-cholesterol
(GE Healthcare Australia Pty. Ltd., Rydalmere, NSW,
Australia), were manufactured at Progen Pharmaceuticals Ltd
and PharmaSynth (Brisbane, Australia). The tyrosine kinase
inhibitor (TKI) sorafenib is an inhibitor of Raf-1 and other
kinases involved in neovascularisation and tumour progression
(Wilhelm et al, 2004) indicated for renal cell carcinoma and HCC.
It was approved by US FDA in 2007 for patients with unresectable
HCC and is the first approved systemic drug therapy for liver
cancer. Sorafenib was sourced from Bayer Health Care (Leverku-
sen, Germany). PG545 was dissolved using cell culture medium for
in vitro or ex vivo experiments and phosphate buffered saline
(PBS), pH 7.2 for in vivo studies.
Cell lines and reagents
LL/2, Hep3b2.1-7 and HT-29 tumour cell lines were obtained from
the American Type Culture Collection and working stocks did
not exceed four passages. MDA-MB-231, PC3, Cal27 and HepG2
were from laboratory stocks at the Diamantina Institute, Brisbane,
Australia. Identity was verified by STR analysis conducted by Cell
Bank Australia (Sydney, Australia) in February 2010. B16F0 was a
gift from Dr Glen Boyle (Queensland Institute of Medical Research,
Brisbane, Australia). Hep3b2.1-7 and PC3 were cultured in RPMI-
1640 (Invitrogen, Mt Waverley, Australia) while MDA-MB-231,
B16F0, HT-29, HepG2, Cal27 and LL/2 were cultured using DMEM
(Invitrogen) and supplemented with 10% fetal bovine serum
(Invitrogen or Hyclone, Logan, UT, USA), 100IUml
 1 penicillin
(Invitrogen), 100mgml
 1 streptomycin (Sigma-Aldrich, Castle Hill,
Australia), 1mM sodium pyruvate (for LL/2 and HepG2 only:
Invitrogen), 25mM HEPES (HepG2: Invitrogen) and 0.4mgml
 1
hydrocortisone (Cal27: Sigma-Aldrich).
Animals
Athymic (nude), SCID, FvB, BALB/c and C57Bl6 mice were
obtained from the Animal Resources Centre (Perth, Australia).
All animal studies were approved by the University of Queensland
or the University of Adelaide Animal Ethics Committees. During
the studies, the care and use of animals was conducted in
accordance with the principles outlined in the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes,
7th Edition, 2004 (National Health and Medical Research Council).
For the HT-29 study, the protocol was approved by the
Institutional Animal Care and Use Committee and the study was
performed at the AAALAC certified animal facility in Pharma
Legacy (Shanghai, China).
In vivo angiogenesis
Angiogenesis in vivo was evaluated using the Angiosponge
model in which subcutaneously implanted, agarose-captured
FGF2 gelfoam sterile sponges (Pfizer, West Ryde, Australia)
induces vascularisation over a 10-day period responsive to
angiogenesis inhibition as determined by the number of vessels
with identifiable lumen that stained positive for CD31/PECAM-1,
an antigen present specifically on endothelial cells (McCarty et al,
2002). PG545 was administered s.c. on the flank distal to the
AngioSponge implant. This method was also used to examine five
medium-sized primary tumours from each group of Lewis Lung
Carcinoma (LL/2)-bearing mice.
Tumour models and drug administration
In the orthotopic Hep3b2.1-7 human liver cancer model, treatment
of mice (n¼10) began 14 days after inoculation of 2.5 10
6 cells.
Mice received PG545 (or [
3H]-PG545 for the efficacy/PK study)
using either a once- or twice-weekly dosing schedule. To initiate
tumour xenografts, MDA-MB-231, PC3, Cal27 and HepG2
cells were injected s.c. into nude mice (n¼8) at 4, 5, 2 and
2 10
7 cells ml
 1, respectively. PG545 was injected s.c. in a
volume of 100–200ml PBS once the average tumour volume was
B100–200mm
3. In the B16F0 lung metastasis model, 2 10
5 cells
were injected via the tail vein of C57Bl6 mice (n¼8). In the
syngeneic LL/2 model, single dose or weekly treatments with
PG545 at 20 or 40mgkg
 1 and sorafenib daily at 60mgkg
 1
commenced on the day of inoculation with 2 10
6 cells. Surface
lung macrometastases were counted for each group (n¼9) upon
study termination. In the intrasplenic HT-29 xenograft model,
1 10
6 cells in 100ml were injected into the spleen. The next day,
PG545 (20mgkg
 1) was administered to mice (n¼12) each week
(qw) over 8 weeks and surface liver and colon metastatic nodules
were counted for each group (n¼12) upon study termination.
Solid tumours were measured in two dimensions (length and
width) and the tumour volume (cm
3) was calculated using the
equation: V¼length width
2 p/6. The anti-tumour activity was
expressed as percent tumour growth inhibition (%TGI). Further
details are available in Supplementary Methods.
PK sampling and analysis
Levels of [
3H]-PG545 determined in blood and tumour samples
collected at 12, 24, 48 and 96h post treatment and levels of PG545
in plasma samples (LC–MS/MS method) collected at 2, 4, 8, 24, 48,
72 and 96h post treatment were determined as outlined in
Supplementary Methods. The PK parameters, Cmax (maximum
plasma concentration), Tmax (time of maximum plasma concen-
tration), kelim (terminal elimination rate constant), t1
2 (half-life)
and AUC (area under the concentration vs time curve) were
derived from the blood [
3H]-PG545 or plasma PG545 concentra-
tion vs time data using model independent methods. Analysis of
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Figure 1 The structure of PG545.
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3H]-PG545 concentration vs time data required use of
a more physiologically based PK model such that tumour
concentrations were estimated from the tumour mass being
perfused with blood containing [
3H]-PG545 and where the blood
[
3H]-PG545 concentration changed over time.
Statistics
For multiple comparisons, a one-way analysis of variance
(ANOVA) followed by a post hoc Holm-Sidak test or a Dunnett’s
test was used, provided the data passed a normality test or the
equal variance test. For comparison between a control and a
treatment group, an unpaired t-test was used. A P-value o0.05 was
considered significant.
RESULTS
PG545 inhibits angiogenesis in vivo
In the AngioSponge model, PG545 was administered either daily or
twice-weekly. Significant inhibition of CD31 staining was observed
(Figure 2A). As the duration of the AngioSponge model is 10 days
in total, once-weekly treatment was not examined in this model.
However, the effect of once-weekly dosing with PG545 on tumour
angiogenesis was determined in tumour-bearing mice (LL/2
model). Assessment of CD31-positively stained vessels with
identifiable lumen in the primary (subcutaneous) tumours of
mice confirmed that once-weekly treatment with PG545 signifi-
cantly inhibited angiogenesis (Figure 2B).
PK profile of radiolabeled PG545 indicates a long half-life
in blood with evidence that efficacious doses penetrate
solid tumours
PG545 significantly reduced solid tumour growth in the orthotopic
liver cancer model Hep3b2.1-7 under two different regimens:
a twice-weekly s.c. administration schedule at 20mgkg
 1
(Figure 3A) or using 20mgkg
 1 as a loading dose followed by a
twice-weekly 10mgkg
 1 maintenance dose (Figure 3B). For
compounds with long half-lives, a loading dose is often used to
quickly increase the plasma concentration of a drug to the desired
steady state levels (Paw, 2006). These dosing schedules resulted in
body weight loss of 9% in the 20mgkg
 1 twice-weekly group and
4% in the 20mgkg
 1 followed by twice-weekly 10mgkg
 1 group
(data not shown). The data generated in separate experiments
using 20mgkg
 1 twice-weekly or as a loading dose (followed by
10mgkg
 1 as a maintenance dose) exhibited a similar efficacy
profile (Tumour Growth inhibition (TGI) values of 52% versus
55%). In combination, twice-weekly dosing with PG545 and
sorafenib (30mgkg
 1, qd) led to a statistically significant
reduction in tumour weight compared with control (TGI¼85%).
Once-weekly dosing with PG545 at 20mgkg
 1 followed by
10mgkg
 1 increased the TGI to 65% compared to the twice-
weekly regimen but the enhanced anti-tumour effects observed in
combination with sorafenib were not improved with once-weekly
dosing (data not shown).
The PK profile of PG545 in tumour-bearing animals was
determined using 20mgkg
 1 [
3H]-PG545 administered s.c. every
96h for a total of three doses. The concentration of PG545 was
assessed in both blood and tumour samples. The PK profile
in blood indicated that the mean elimination half-life (t1
2)o f
[
3H]-PG545 was 450h for mice administered up to three s.c. bolus
doses at 96h intervals (Table 1). Visual inspection of the mean
blood [
3H]-PG545 concentrations vs time curve data showed that
the mean blood Cmax values were in the range 25.9–29.0mgml
 1
and the corresponding mean Tmax values were in the range 2–6h
(Figure 3C).
Visual inspection of the mean tumour [
3H]-PG545 concentra-
tion vs time curve data showed that the tumour Cmax values were in
the range 36.6–45.1mgg
 1 and that the corresponding mean Tmax
values in the tumour tissue were 12h (one dose), 48h (two doses)
and X96h (three doses) (Figure 3D). Using a one-compartment
PK model, the estimated mean rate constant for uptake of
[
3H]-PG545 from the bloodstream into the tumour (t1
2b), derived
from the mean blood and tumour concentration vs time data, was
in the range 12.8–16.5h. The corresponding estimated mean t1
2 for
return of [
3H]-PG545 from the tumour into the bloodstream (t1
2t),
derived from the mean blood and tumour concentration vs time
data, was in the range 15.7–16.3h (Supplementary data, Supple-
mentary Table S1). The Cmax values in liver and kidney reached
106 and 39mgg
 1, respectively, following a single dose (data not
shown). This equates to a tumour:liver ratio of 0.4 and a
tumour:kidney ratio of 1.3, 12h after a single dose, suggesting
good distribution into tumour tissue compared with other organs.
As a comparison, gefitinib (Iressa, Astra Zeneca, London, UK) has
a tumour:liver ratio of 0.15 or 0.18 and a tumour:kidney ratio of
0.35 or 0.56, 2h or 8h, respectively, after a single dose in LoVo
tumour xenografts (McKillop et al, 2005).
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Figure 2 PG545 inhibits angiogenesis in vivo.( A) PG545 treatment was
shown to possess anti-angiogenic activity in the AngioSponge model
following evaluation of CD31/PECAM-1 positive endothelial cells after
immunohistochemical staining of blood vessels.
##Po0.01 vs vehicle
control without FGF-2; **Po0.01 vs vehicle control and FGF-2. (B)
Treatment with PG545 at 20 and 40mgkg
 1 once-weekly (s.c.) resulted
in a significant (Po0.001) decrease in CD31 endothelial staining in tumours
by 30 and 22%, respectively.
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xenograft models
Further investigation of once- or twice-weekly s.c. dosing
schedules was performed in a variety of xenograft or syngeneic
cancer models (Figure 4). Tumour growth inhibition in the
MDA-MB-231 model (Figure 4A) was maximal at 20mgkg
 1 once-
weekly (77%) or 20mgkg
 1 twice-weekly (71%) with 30mgkg
 1
groups inhibiting tumour growth by 69% (30mgkg
 1, once-
weekly) or 59% (30mgkg
 1, twice-weekly). Body weight loss at
the end of the study was 4% for 20mgkg
 1 once-weekly, 6% for
20mgkg
 1 twice-weekly, 11% for 30mgkg
 1 once-weekly and
10% for 30mgkg
 1 twice-weekly (data not shown). Employing the
20mgkg
 1 dose only in subsequent models, the differences noted
between once- and twice-weekly schedules were not significant in
the PC3 or HepG2 models. For example, in the PC3 model, once-
weekly dosing led to a TGI of 74% while twice-weekly dosing
resulted in a TGI of 83% (Figure 4B). Although body weight loss at
20mgkg
 1 once-weekly was 6%, the twice-weekly regimen was
16% (data not shown). However, in the HepG2 model (Figure 4C),
the once-weekly (TGI¼55%), but not twice-weekly (TGI¼45%)
schedule, significantly inhibited tumour growth to a similar extent
as 20mgkg
 1 once-weekly treatment in the Cal27 model which
produced a TGI of 57% (Figure 4D). In both models, 20mgkg
 1
once-weekly (and twice-weekly in the HepG2 model) led to body
weight loss between 2% and 4% (data not shown). PG545 also
significantly reduced primary tumour growth in the HT-29 model
(Supplementary Figure S1a). The concentration of PG545 that is
lethal to 50% of cells (LC50) using HUVEC (78mM), B16 (4200mM)
or HepG2 cells (4100mM), indicated that PG545 is not cytotoxic
in vitro (data not shown).
PG545 induces potent anti-metastatic effects in
experimental and spontaneous models of metastasis
Twice-weekly injections of PG545 significantly inhibited the
formation of metastases in the B16F0 experimental lung metastasis
model, when administered either before or on the day of tumour
cell inoculation (Figure 5A). When administered as a once-weekly
schedule, PG545 also significantly inhibited the occurrence of
spontaneously arising liver metastases (Figure 5B; Supplementary
Figure S1b) and colon metastases (Figure 5C) in the HT-29 colon
model. In terms of body weight loss, the nadir was 8% in the B16
model and 12% in the HT-29 model (data not shown).
The Lewis Lung Carcinoma model (LL/2) provided another
model to investigate the effect of PG545 on spontaneous
metastasis. PG545 was administered at weekly intervals or in
some cases, as a single injection from the day of tumour
inoculation. The body weight nadir during the study constituted
a loss of 5% (data not shown). In addition to significant inhibition
of primary tumour growth (Figure 6A), PG545 significantly
reduced the number of lung metastases, with complete abrogation
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Figure 3 The anti-tumour activity of PG545 in the orthotopic HCC model Hep3b2.1-7 can be enhanced by addition of sorafenib and exhibits
favourable PK profiles in blood and tumour tissue. (A) Efficacy of PG545 when administered at 20mgkg
 1 twice-weekly. (B) Efficacy of PG545 alone and
in combination with sorafenib, when administered using a loading dose of 20mgkg
 1 followed by a twice-weekly maintenance dose
of 10mgkg
 1.( C) Actual and estimated mean concentration vs time curve data for [
3H]-PG545 in blood following administration of three bolus doses
of [
3H]-PG545 at 20mgkg
 1 at 96h intervals. (D) Actual and estimated mean concentration vs time curve data in tumour tissue of mice treated with three
doses of [
3H-PG545] at 20mgkg
 1, 96h apart. *Po0.05 vs vehicle control (unpaired t-test or ANOVA followed by Dunnett’s test).
Table 1 Model independent pharmacokinetic analysis of blood
[
3H]-PG545 in tumour-bearing mice (Hep3b model) administered at
20mgkg
 1 every 96h
Parameter First dose Second dose Third dose
Cmax (mgml
 1)2 8 2 6 2 9
Tmax (h) 4 2 6
t1
2 (h) 65 ND 117
AUC0 t (mg.hml
 1) 991 1208 1556
Abbreviation: AUC¼area under the concentration vs time curve. Note: t1
2 after
second dose could not be determined (ND) as blood concentrations for at least four
half-lives are required to provide accurate estimates of elimination rate constant.
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 1 group and 96% inhibition in the
20mgkg
 1 once-weekly group (Figure 6B). However, it is not clear
why 40mgkg
 1 once-weekly failed to reach significance but
interestingly sorafenib demonstrated no effect on metastasis in
this model. Plasma concentration vs time curves indicated that
efficacious exposure levels should be between 20 and 70mgml
 1
(Figure 6C) and PK analysis revealed the apparent t1
2 to range
between 28 and 39h with a Cmax, Tmax and to a lesser extent, an
AUC, comparable to that observed in the liver cancer model using
the radiolabeled compound (Table 2). The difference between the
half-life estimation of [
3H]-PG545 and PG545 by LC/MS/MS may
be explained by experimental variations/matrices and the possi-
bility that the radiolabel was no longer attached to the parent
molecule, thus estimating the t1
2 for removal of a metabolite to
which the label is attached.
DISCUSSION
Heparanase-mediated degradation of HS is involved in tumour
angiogenesis and metastasis, making it a major target for cancer
research (Hammond et al, 2006; McKenzie, 2007; Barash et al,
2010). Clinical studies have typically noted a poorer prognosis in
patients with high expression of heparanase, presumably due to its
association with an aggressive, metastatic phenotype (Chen et al,
2008; Mikami et al, 2008; Rivera et al, 2008; Zheng et al, 2009). The
pivotal role of VEGF and its receptors in promoting angiogenesis is
also well established, and both antibody and small-molecule
inhibitors of VEGF signaling have shown clinical utility. Despite no
specific FGF inhibitors being clinically available, their relevance
as a cancer therapy has become increasingly clear due to the
increased expression of FGF family members in late-stage tumours
following phenotypic resistance to VEGFR2 blockade (Casanovas
et al, 2005). We previously identified a series of HS mimetics, of
which PG545 was one, as potent inhibitors of heparanase, GFs
including VEGF and FGFs and ex vivo angiogenesis (Dredge et al,
2010). Herein, we extend those findings to the pre-clinical arena to
demonstrate the in vivo potency of PG545 in angiogenesis, solid
tumour and metastasis models and provide initial data on the
pharmacokinetics associated with the compound.
The AngioSponge model highlighted that daily and twice-weekly
dosing with PG545 induced a potent anti-angiogenic effect in vivo,
as measured by CD31 expression. In the LL/2 model, decreases
in CD31 expression were also statistically significant using once-
weekly dosing. Unfortunately, as only five representative medium-
sized tumours from each group were available, any dose-
dependent correlation between reduction in CD31 staining and
inhibition of solid tumour growth is not apparent. Overall, the
data confirmed that a once- or twice-weekly dosing schedule is
anti-angiogenic in vivo and this schedule is less frequent compared
with those of other heparin-derived products or HS mimetics
(Gandhi and Mancera, 2010). The body weight loss in mice may be
species-specific because PG545 is not cytotoxic in vitro or in vivo
(vacuolation was most common pathology finding) and did not
lead to significant body weight loss in other species during toxicity
studies (data not shown). The absence of bruising in PG545-treated
nude mice illustrates the mild anti-coagulant properties of PG545
(Dredge et al, 2010). Although high doses of PG545 increased
activated partial thromboplastin time (which was reversible)
in toxicology studies, it is not clear whether this is due to
a depletion of clotting factors or a mild anti-coagulant effect
(data not shown).
PK data were generated using radiolabeled PG545 administered
to satellite groups of tumour-bearing mice (Hep3b2.1-7). A
relatively long half-life (t1
2) in blood (450h) was observed. The
concentrations of [
3H]-PG545 measured within the liver tumours
of mice confirmed entry into tumour tissue. A one-compartment
PK model found each of the estimated parameter values was
internally consistent following administration of one, two or three
doses (Supplementary data; Supplementary Table S1). However,
visual inspection of the graph for tumour-bearing mice adminis-
tered three doses of [
3H]-PG545, with each dose separated by a
96-h interval, showed that the tumour concentration vs time curve
for the third dose is different from that for the preceding two
doses. The reason for this is unclear though it is possible that
PG545 could have induced biological change within the tumour
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Figure 4 PG545 significantly inhibits solid tumour progression in (A) breast (MDA-MB-231), (B) prostate (PC3), (C) liver (HepG2) and (D) head and
neck (Cal27) cancer models. Treatment commenced once tumours reached 100–200mm
3.* Po0.05 vs vehicle control, **Po0.01 vs vehicle control
(repeated measures ANOVA followed by Dunnett’s post hoc test, n¼8–10 per group depending on study). TGI values are also shown.
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svasculature – such an assumption would not necessarily be
applicable to the one-compartment PK model.
Tumour growth in the Hep3b2.1-7 model was significantly
reduced following the once- and twice-weekly dosing schedule for
PG545 or using a loading and maintenance dose approach, to
an extent similar to that seen following treatment with sorafenib,
a TKI approved for HCC. The combination of PG545 and sorafenib
produced a TGI up to 85%, thus illustrating some potential utility
for combination modalities using PG545. Taken together with the
PK profile, the efficacy data indicated that once-weekly dosing may
provide an optimal dosing frequency for PG545. This was further
confirmed using a variety of subcutaneously implanted xenograft
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Figure 5 PG545 significantly inhibits metastases in the B16 experimental
metastasis model for melanoma and the spontaneous metastasis model
HT-29 (colon). (A) PG545 administered on days indicated either before or
after tumour cell inoculation (Day 0) reduced metastatic development in
the lungs of mice in the B16 model. (B) PG545 treatment once-weekly
over 8 weeks completely prevented metastasis to the liver in the HT-29
model. (C) PG545 treatment once-weekly over 8 weeks significantly
reduced metastasis to the colon in the HT-29 model. Data are presented
as mean number of lung, liver or colon metastases with s.e. *Po0.05,
**Po0.01 vs vehicle control (one-way ANOVA followed by Dunnett’s test
for B16 model or t-test for HT-29 model).
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Figure 6 PG545 significantly inhibits solid tumour progression and
spontaneous metastasis in the Lewis Lung Carcinoma model (LL/2).
(A) PG545 treatment once-weekly (total 3 weeks) significantly inhibited
solid tumour growth. (B) Either a single injection or weekly dosing inhibited
metastasis, which was significant in the 20mgkg
 1 1  week group and
the 40mgkg
 1 single dose group, whereas sorafenib had no effect
on metastasis. Data are presented as mean number of lung meta-
stases with s.e. (C) PG545 plasma concentration vs time curves following
a once-weekly dose of PG545 in week 1 and week 2. *Po0.05 vs vehicle
control (one-way ANOVA followed by Holm-Sidak test or Dunnett’s
test).
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sor syngeneic models of prostate, breast, liver and head and neck
cancer in the mouse.
We next tested the anti-metastatic activity of PG545 in three
murine models of metastasis. In the B16 melanoma model, short-
term therapy with PG545 was initiated either before or immedi-
ately after i.v. tumour inoculation of B16 cells and confirmed
that both schedules significantly inhibited the development of
lung metastases. In the spontaneously metastasising HT-29 colon
model, complete abrogation of liver metastases was achieved using
a weekly regimen of 20mgkg
 1 PG545 over 8 weeks (a dose in
week 6 was omitted due to body weight concerns). In the
spontaneously metastasising Lewis Lung Carcinoma model,
PG545 significantly reduced the number of metastases and PK
data estimated the efficacious plasma concentration range starts at
B20mgml
 1. This potent anti-metastatic effect of PG545 may
differentiate it from other angiogenesis inhibitors, which have
been associated with an acceleration of metastasis under certain
circumstances (Ebos et al, 2009; Paez-Ribes et al, 2009). It is
hypothesised that a metastatic ‘conditioning’ effect may occur
via multiple mechanisms following treatment with angiogenesis
inhibitors (Ebos et al, 2009; Paez-Ribes et al, 2009) which posed
the question – are there any alternative anti-angiogenic agents that
might not evoke this malignant behaviour? (Loges et al, 2009).
Thus, further elucidation of the contrasting mechanisms of action
and possible differences in efficacy between HS mimetics and TKI/
biologics is warranted.
In conclusion, we have clearly demonstrated the anti-tumour
and anti-metastatic properties of PG545, which to our knowledge
is the first HS mimetic that is a single molecular entity to emerge
as a clinical candidate. In addition to its anti-angiogenic proper-
ties, it is the anti-heparanase/anti-metastatic activity that may
differentiate PG545 from other anti-angiogenic agents. Particularly
in light of recent preclinical findings relating primarily to anti-
VEGF therapies, this property may become a critical attribute as
PG545 progresses towards the clinic.
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